| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Eli Lilly is making significant strides in product and service development, particularly in the area of cholesterol drug development and innovative treatments that address obesity and other health issues. Recent successful clinical trials have showcased the effectiveness of their leading products, especially tirzepatide, which has demonstrated substantial health benefits. This innovation not only enhances treatment outcomes for patients but also positions Lilly as a leader in cardiovascular and metabolic health solutions. However, ongoing market competition and regulatory hurdles remain critical challenges that could impact development timelines. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The market sentiment at 0.3 is modestly bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for LLY since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.5, and the negative at -0.2 on 2024-11-19. The forces of and Valuation Sentiment (-1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (3.1) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| LLY | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-19 | 0%(0%) | 0 | 0% | 0.4 | 3.1 | -1 | |||||||
| 2024-11-05 | 0%(0%) | 0 | 0% | 0.3 | 2.8 | -1 | |||||||
| 2024-11-04 | 0%(0%) | 0 | 0% | 0.2 | 2.3 | -1 | |||||||
| 2024-10-31 | 0%(0%) | 0 | 0% | 0 | 1.1 | -1 | |||||||
| 2024-10-30 | 0%(0%) | 0 | 0% | -0.1 | 0.5 | -1 | |||||||
| 2024-10-29 | 0%(0%) | 0 | 0% | 0.1 | 1.7 | -1 | |||||||
| 2024-10-22 | 0%(0%) | 0 | 0% | 0.1 | 1.4 | -1 | |||||||
| 2024-10-17 | 0%(0%) | 0 | 0% | -0.4 | -1.1 | -1 | |||||||
| 2024-10-03 | 0%(0%) | 0 | 0% | -0.4 | -1.3 | -1 | |||||||
| 2024-09-18 | 0%(0%) | 0 | 0% | -0.3 | -0.8 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-05-19 17:20:48 Eli Lilly's focus on treatments for high-risk cardiovascular patients illustrates a broader trend in the industry towards managing and mitigating health risks. |
| 2025-05-19 17:20:48 The investment by Dexcom in Oura represents strategic movements in the health sector that may influence Eli Lilly's partnerships and market position. |
| 2025-05-19 17:20:48 The successful mid-stage trial results for Eli Lilly's oral cholesterol drug underline the effectiveness of their pharmaceutical research and development efforts. |
| 2025-05-19 17:20:48 The positive results from Eli Lilly's cholesterol pill trial signal advancements in cardiovascular medications, highlighting the company's innovation in healthcare solutions. |
| 2025-05-19 17:20:48 Eli Lilly's announcement regarding changes in their board of directors indicates a shift in company leadership that may impact future strategies. |